Featured image: A scientist pipettes laboratory samples. Contextual research photograph; not a Rina-S trial participant or trial site. Photo: Julia Koblitz / Unsplash. Unsplash licence.
A tumour shrinking is an important result. Proving that a new cancer medicine improves outcomes compared with another treatment is a further step. The latest Rina-S ovarian cancer results sit between those two milestones.
On 3 October 2026, Genmab reported results from Part C of RAINFOL-01 at the International Gynecologic Cancer Society meeting. Among 109 treated participants, the objective response rate was 45.9%, and median response duration was 12.1 months. The company’s conference-results announcement describes investigational treatment in platinum-resistant ovarian cancer. It is not a regulatory approval or a finding that cancer has been cured.
An antibody carries a potent drug
Rina-S, also called rinatabart sesutecan, belongs to the antibody-drug conjugate family. These medicines join an antibody, which recognises a marker on cells, to a drug payload. The aim is to bring the payload to cells bearing the target rather than distribute it without that targeting step. The National Cancer Institute provides a plain-language definition of antibody-drug conjugates.
For Rina-S, the target is folate receptor alpha, commonly shortened to FRα, and the payload is exatecan, which interferes with an enzyme involved in managing DNA during cell division. The link between antibody and payload is also part of the drug’s design. Genmab’s description of the investigational medicine.
Targeting does not make a drug free of adverse effects. The antibody, linker and payload operate together, and the clinical question includes both anticancer activity and what patients experience during treatment.
The response numbers have a defined meaning
An objective response rate counts participants whose cancer meets specified criteria for a partial or complete response. It does not count everyone as cured. Median response duration applies to the responding group; it is not the time every enrolled participant benefited.
The RAINFOL-01 registry identifies the study as Phase I/II, open label and non-randomized. Its response assessments and safety measures are specified in the trial record. In an open-label study, researchers and participants know which treatment is being given. Non-randomized means these findings do not come from a randomly allocated comparison with a control treatment.
Genmab also reported serious adverse events in roughly one-third of the cohort. Common events included nausea, fatigue, anaemia and neutropenia, the last meaning a reduced count of a type of infection-fighting white blood cell. Reported safety findings. These results need to be read alongside the response figures, rather than left outside the story.
The larger study asks a different question
The RAINFOL-02 registry describes a randomized, open-label Phase III study comparing Rina-S with treatment chosen by investigators. Its primary outcome is progression-free survival: the time before cancer progresses or a participant dies. Other measures include overall survival, response duration and quality of life.
Randomization helps create groups whose starting differences are less likely to explain the result. It does not eliminate every uncertainty, but it offers a stronger basis for asking whether the new medicine provides benefit relative to another approach.
The distinction between trial stages is useful here. Early studies examine safety and signs of activity; later comparative studies test benefit in a more structured way. The NCI explains why clinical trials build evidence in stages. The new conference report should not be substituted for the Phase III comparison.
A meaningful signal with further evidence to earn
Our reading is that durable responses in a previously treated population make this a development worth following. The next assessment should keep the denominator visible, include adverse effects, and examine comparative outcomes rather than isolate the most striking percentage.
Conference results released by a sponsor are also a particular type of evidence. They can communicate important clinical observations quickly, but readers should look for the complete scientific presentation, subsequent peer-reviewed reporting and results from the randomized study.
The advance is a clearer picture of Rina-S activity in this cohort. Whether it becomes a useful new approved option will depend on the broader clinical and regulatory evidence, not on the headline response rate alone.
Reporting and source checks completed on 5 October 2026. By FutureTechDose Editor.
Leave a Reply